Cargando…
[(68)Ga]Ga-PSMA-11 PET imaging as a predictor for absorbed doses in organs at risk and small lesions in [(177)Lu]Lu-PSMA-617 treatment
INTRODUCTION: Patient eligibility for [(177)Lu]Lu-PSMA therapy remains a challenge, with only 40–60% response rate when patient selection is done based on the lesion uptake (SUV) on [(68)Ga]Ga-PSMA-PET/CT. Prediction of absorbed dose based on this pre-treatment scan could improve patient selection a...
Autores principales: | Peters, Steffie M. B., Hofferber, Regina, Privé, Bastiaan M., de Bakker, Maarten, Gotthardt, Martin, Janssen, Marcel, de Lange, Frank, Muselaers, Constantijn H. J., Mehra, Niven, Witjes, J. Alfred, Costa, Pedro F., Nagarajah, James, Konijnenberg, Mark W., Jentzen, Walter |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8921092/ https://www.ncbi.nlm.nih.gov/pubmed/34623453 http://dx.doi.org/10.1007/s00259-021-05538-2 |
Ejemplares similares
-
Intra-therapeutic dosimetry of [(177)Lu]Lu-PSMA-617 in low-volume hormone-sensitive metastatic prostate cancer patients and correlation with treatment outcome
por: Peters, Steffie M. B., et al.
Publicado: (2021) -
Kidney absorbed radiation doses for [(177)Lu]Lu-PSMA-617 and [(177)Lu]Lu-PSMA-I&T determined by 3D clinical dosimetry
por: Uijen, Maike J.M., et al.
Publicado: (2023) -
Urinary excretion kinetics of [(177)Lu]Lu-PSMA-617
por: de Bakker, Maarten, et al.
Publicado: (2023) -
(44)Sc-PSMA-617 for radiotheragnostics in tandem with (177)Lu-PSMA-617—preclinical investigations in comparison with (68)Ga-PSMA-11 and (68)Ga-PSMA-617
por: Umbricht, Christoph A., et al.
Publicado: (2017) -
Optimization of the radiation dosimetry protocol in Lutetium-177-PSMA therapy: toward clinical implementation
por: Peters, Steffie M. B., et al.
Publicado: (2023)